Role of PDEs in vascular health and disease: Endothelial PDEs and angiogenesis

Cyclic Nucleotide Phosphodiesterases in Health and Disease

Volumn , Issue , 2006, Pages 417-439

  Keravis, Thérèse ^a   Silva, Antonio P ^b   Favot, Laure ^c   Lugnier, Claire ^d  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b NOVARTIS PHARMA AG   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

^d CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 70349132737     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (59)

1. Furchgott, R.F., and J.V. Zawadzki. 1980. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288:373.
2. Palmer, R.M., A.G. Ferrige, and S. Moncada. 1987. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327:524.
3. Arnold, W.P., et al. 1977. Nitric oxide activates guanylate cyclase and increases guanosine 3',5'-cyclic monophosphate levels in various tissue preparations. Proc Natl Acad Sci USA 74:3203.
4. Furchgott, R.F., and P.M. Vanhoutte. 1989. Endothelium-derived relaxing and contracting factors. FASEB J 3:2006.
5. Folkman, J. 1995. Angiogenesis in cancer, vascular, rheumatoid, and other disease. Nat Med 1:27.
6. Papapetropoulos, A., et al. 1997. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J Clin Invest 100:3131.
7. Hood, J., and H.J. Granger. 1998. Protein kinase G mediates vascular endothelial growth factor-induced Raf-1 activation and proliferation in human endothelial cells. J Biol Chem 273:23504.
8. Leitman, D.C., R.R. Fiscus, and F. Murad. 1986. Forskolin, phosphodiesterase inhibitors, and cyclic AMP analogues inhibit proliferation of cultured bovine aortic endothelial cells. J Cell Physiol 127:237.
9. Lugnier, C., and V.B. Schini. 1990. Characterization of cyclic nucleotide phosphodiesterases from cultured bovine aortic endothelial cells. Biochem Pharmacol 39:75.
10. Souness, J.E., et al. 1990. Pig aortic endothelial-cell cyclic nucleotide phosphodiesterases. Use of phosphodiesterase inhibitors to evaluate their roles in regulating cyclic nucleotide levels in intact cells. Biochem J 266:127.
11. Lugnier, C., et al. 1985. Substituted carbostyrils as inhibitors of cyclic AMP phosphodiesterase. Eur J Med Chem 20:121.
12. Yamamoto T., et al. 1983. Complex effects of inhibitors on cyclic GMP-stimulated cyclic nucleotide phosphodiesterase. J Biol Chem 258:14173.
13. Wu, A.Y., et al. 2004. Molecular determinants for cyclic nucleotide binding to the regulatory domains of phosphodiesterase 2A. J Biol Chem 279:37928.
14. Rybalkin, S.D., et al. 2003. PDE5 is converted to an activated state upon cGMP binding to the GAF A domain. EMBO J 22:469.
15. Lugnier, C., et al. 1986. Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta. Biochem Pharmacol 35:1743.
16. Prigent, A.F., et al. 1988. Comparison of cyclic nucleotide phosphodiesterase isoforms from rat heart and bovine aorta. Separation and inhibition by selective reference phosphodiesterase inhibitors. Biochem Pharmacol 37:3671.
17. Ashikaga, T., S.J. Strada, and W.J. Thompson. 1997. Altered expression of cyclic nucleotide phosphodiesterase isozymes during culture of aortic endothelial cells. Biochem Pharmacol 54:1071.
18. Keravis, T., N. Komas, and C. Lugnier. 2000. Cyclic nucleotide hydrolysis in bovine aortic endothelial cells in culture: Differential regulation in cobblestone and spindle phenotypes. J Vasc Res 37:235.
19. Suttorp, N., et al. 1993. Role of phosphodiesterases in the regulation of endothelial permeability in vitro. J Clin Invest 91:1421.
20. Zhu, B., S. Strada, and T. Stevens. 2005. Cyclic GMP-specific phosphodiesterase 5 regulates growth and apoptosis in pulmonary endothelial cells. Am J Physiol Lung Cell Mol Physiol 289:L196.
21. Thompson, W.J., et al. 2002. Regulation of cyclic AMP in rat pulmonary microvascular endothelial cells by rolipram-sensitive cyclic AMP phosphodiesterase (PDE4). Biochem Pharmacol 63:797.
22. Bauer, J., et al. 1992. In vitro model of angiogenesis using a human endothelium-derived permanent cell line: Contributions of induced gene expression, G-proteins, and integrins. J Cell Physiol 153:437.
23. Ilan, N., S. Mahooti, and J.A. Madri. 1998. Distinct signal transduction pathways are utilized during the tube formation and survival phases of in vitro angiogenesis. J Cell Sci 111:3621.
24. Edgell, C.J., C.C. McDonald, and J.B. Graham. 1983. Permanent cell line expressing human factor VIII-related antigen established by hybridization. Proc Natl Acad Sci USA 80:3734.
25. Favot, L., T. Keravis, and C. Lugnier. 2000. Controle de l'angiogenèse tumorale par les inhibiteurs de phosphodiesterases (PDEs). Arch Mal Coeur 93:432, A 4-2.
26. Hayashi, T., et al. 1995. Estrogen increases endothelial nitric oxide by a receptor-mediated system. Biochem Biophys Res Commun 214:847.
27. Favot. L., et al. 2003. VEGF-induced HUVEC migration and proliferation are decreased by PDE2 and PDE4 inhibitors. Thromb Haemost 90:334.
28. Miro, X., et al. 2000. Phosphodiesterases 4D and 7A splice variants in the response of HUVEC cells to TNF-a. Biochem Biophys Res Commun 274:415.
29. Sadhu, K., et al. 1999. Differential expression of the cyclic GMP-stimulated phosphodiesterase PDE2A in human venous and capillary endothelial cells. J Histochem Cytochem 47:895.
30. Netherton, S., and D.H. Maurice. 2005. Vascular endothelial cell cyclic nucleotide phosphodiesterases and regulated migration: Implications in angiogenesis. Mol Pharmacol 67:263.
31. D'Andrea, M.R., et al. 2005. Expression of PDE11A in normal and malignant human tissues. J Histochem Cytochem 53:895.
32. Lugnier, C., and N. Komas. 1993. Modulation of vascular cyclic nucleotide phosphodiesterases by cyclic GMP: Role in vasodilatation. Eur Heart J 14:141.
33. Boulanger, C., et al. 1990. Stimulation of cyclic GMP production in cultured endothelial cells of the pig by bradykinin, adenosine diphosphate, calcium ionophore A23187, and nitric oxide. Br J Pharmacol 101:152.
34. Schmidt, K., W.F. Graier, and W.R. Kukovetz. 1990. EDRF-formation increases cGMP-levels in cultured endothelial cells. Adv Second Messenger Phosphoprotein Res 24:455.
35. Kessler, T., and C. Lugnier. 1995. Rolipram increases cyclic GMP content in L-arginine-treated cultured bovine aortic endothelial cells. Eur J Pharmacol 290:163.
36. Heijnen, H.F., et al. 2004. Colocalization of eNOS and the catalytic subunit of PKA in endothelial cell junctions: A clue for regulated NO production. J Histochem Cytochem 52:1277.
37. Butt, E., et al. 2000. Endothelial nitric-oxide synthase (type III) is activated and becomes calcium independent upon phosphorylation by cyclic nucleotide-dependent protein kinases. J Biol Chem 275:5179.
38. Graier, W.F., et al. 1992. Increases in endothelial cyclic AMP levels amplify agonist-induced formation of endothelium-derived relaxing factor (EDRF). Biochem J 288:345.
39. Favot, L., T. Keravis, and C. Lugnier. 2004. Modulation of VEGF-induced endothelial cell cycle protein expression through cyclic AMP hydrolysis by PDE2 and PDE4. Thromb Haemost 92:634.
40. Podzuweit, T., P. Nennstiel, and A. Muller. 1995. Isozyme selective inhibition of cGMP-stimulated cyclic nucleotide phosphodiesterases by erythro-9-(2-hydroxy-3-nonyl)adenine. Cell Signal 7:733.
41. Raeburn, D., et al. 1994. Antiinflammatory and bronchodilator properties of RP 73401, a novel and selective phosphodiesterase type IV inhibitor. Br J Pharmacol 113:1423.
42. Lugnier, C. 2000. Unpublished data.
43. Schaeffer, H.J., and C.F. Schwender. 1974. Enzyme inhibitors: Bridging hydrophobic and hydrophilic regions on adenosine deaminase with some 9-(2-hydroxy-3-alkyl)adenines. J Med Chem 17:6.
44. Smolenski, R.T., et al. 1994. Endothelial nucleotide catabolism and adenosine production. Cardiovasc Res 8:100.
45. Sexl, V., et al. 1995. Stimulation of human umbilical vein endothelial cell proliferation by A2-adrenosine and β2-adrenoceptors. Br J Pharmacol 114:1577.
46. Hordijk, P.L., et al. 1994. cAMP abrogates the p21ras-mitogen-activated protein kinase pathway in fibroblasts. J Biol Chem 269:3534.
47. Koyama, H., et al. 2001. Molecular pathways of cyclic nucleotide-induced inhibition of arterial smooth muscle cell proliferation. J Cell Physiol 186:1.
48. Cook, S.J., and F. McCormick. 1993. Inhibition by cAMP of Ras-dependent activation of Raf. Science 262:1069.
49. Vadiveloo, P.K., et al. 1997. G1 phase arrest of human smooth muscle cells by heparin, IL-4 and cAMP is linked to repression of cyclin D1 and cdk2. Atherosclerosis 133:61.
50. Nigg, E.A. 1993. Targets of cyclin-dependent protein kinases. Curr Opin Cell Biol 5:187.
51. Vidal, A., and A. Koff. 2000. Cell-cycle inhibitors: Three families united by a common cause. Gene 247:1.
52. Lugnier, C., et al. 1999. Characterization of cyclic nucleotide phosphodiesterase isoforms associated to isolated cardiac nuclei. Biochim Biophys Acta 1472:431.
53. Lugnier, C. 2006. Cyclic nucleotide phosphodiesterase (PDE) superfamily: A new target for the development of specific therapeutic agents. Pharmacol Ther 109:366.
54. Houslay, M.D., and D.R. Adams. 2003. PDE4 cAMP phosphodiesterases: Modular enzymes that orchestrate signaling cross-talk, desensitization, and compartmentalization. Biochem J 370:1.
55. Dell'Acqua, M.L., and J.D. Scott. 1997. Protein kinase A anchoring. J Biol Chem 272:12881.
56. Kim, S., M. Harris, and J.A. Varner. 2000. Regulation of integrin a vβ 3-mediated endothelial cell migration and angiogenesis by integrin a5β 1 and protein kinase A. J Biol Chem 275:33920.
57. Kim, S., et al. 2002. Inhibition of endothelial cell survival and angiogenesis by protein kinase A. J Clin Invest 110:933.
58. Palmer, D., K. Tsoi, and D.H. Maurice. 1998. Synergistic inhibition of vascular smooth muscle cell migration by phosphodiesterase 3 and 4 inhibitors. Circ Res 82:582.
59. Vandecasteele G., et al. 2001. Cyclic GMP regulation of the L-type Ca2+ channel current in human atrial myocytes. J Physiol 533:329.